You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Montanide

Showing 176 - 200 of 229
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Renal Cell Carcinoma Trial in Chicago (G250 peptide, IL-2)

Terminated
  • Metastatic Renal Cell Carcinoma
  • Chicago, Illinois
    The University of Chicago
Sep 4, 2013

Epithelial Ovarian, Tubal or Peritoneal Cancer Trial in Durham (tumor peptide vaccine)

Completed
  • Epithelial Ovarian, Tubal or Peritoneal Cancer
  • tumor peptide vaccine
  • Durham, North Carolina
    Duke Comprehensive Cancer Center
Nov 15, 2012

Melanoma (Skin), Solid Tumor Trial run by the NCI (aldesleukin, incomplete Freund's adjuvant, telomerase: 540-548 peptide

Completed
  • Melanoma (Skin)
  • Unspecified Adult Solid Tumor, Protocol Specific
  • aldesleukin
  • +2 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Studies Sup
Jun 17, 2013

Melanoma (Skin) Trial run by the NCI (aldesleukin, incomplete Freund's adjuvant, recombinant tyrosinase-related protein-2)

Completed
  • Melanoma (Skin)
  • aldesleukin
  • +2 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Studies Sup
Jun 17, 2013

Melanoma (Skin) Trial run by the NCI (aldesleukin, gp100 antigen, incomplete Freund's adjuvant)

Completed
  • Melanoma (Skin)
  • aldesleukin
  • +2 more
  • Bethesda, Maryland
  • +1 more
Jun 18, 2013

Melanoma Trial run by the NCI (Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51)

Completed
Has Results
  • Melanoma
  • Glycoprotein 100 (GP100): 209-217 (210M)
  • +5 more
  • Bethesda, Maryland
    National Cancer Institute (NCI)
Oct 17, 2012

Melanoma (Skin) Trial run by the NCI (aldesleukin, gp100 antigen, incomplete Freund's adjuvant)

Completed
  • Melanoma (Skin)
  • aldesleukin
  • +3 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Studies Sup
Jun 18, 2013

Melanoma (Skin) Trial in United States (aldesleukin, gp100 antigen, incomplete Freund's adjuvant)

Completed
  • Melanoma (Skin)
  • aldesleukin
  • +2 more
  • Duarte, California
  • +8 more
Jun 25, 2013

Pancreatic Cancer Trial in Fukushima (VEGFR1-1084, VEGFR2-169, and gemcitabine)

Unknown status
  • Pancreatic Cancer
  • VEGFR1-1084, VEGFR2-169, and gemcitabine
  • Fukushima, Japan
    Fukushima Medical University Hospital
Mar 13, 2013

Pancreatic Cancer Trial in Fukushima (VEGFR1-1084, VEGFR2-169, Gemcitabine)

Completed
  • Pancreatic Cancer
  • Fukushima, Japan
    Fukushima Medical University Hospital
Mar 13, 2013

Non Small Cell Lung Cancer Trial in Fukushima (HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2)

Completed
  • Non Small Cell Lung Cancer
  • HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2
  • Fukushima, Japan
    Fukushima Medical University
Aug 13, 2013

Non Small Cell Lung Cancer Trial in Fukushima (HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2)

Completed
  • Non Small Cell Lung Cancer
  • HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2
  • Fukushima, Fuskushima, Japan
    Fukushima Medical University Hospital
Aug 13, 2013

Melanoma (Skin) Trial run by the NCI (aldesleukin, incomplete Freund's adjuvant, sargramostim)

Completed
  • Melanoma (Skin)
  • aldesleukin
  • +4 more
  • Bethesda, Maryland
    Surgery Branch
Jun 19, 2013

Melanoma (Skin) Trial run by the CC (gp100 antigen, incomplete Freund's adjuvant, ipilimumab)

Completed
  • Melanoma (Skin)
  • gp100 antigen
  • +2 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Studies Sup
Jun 21, 2012

Melanoma (Skin) Trial run by the NCI (aldesleukin, gp209-2M antigen, incomplete Freund's adjuvant)

Completed
  • Melanoma (Skin)
  • aldesleukin
  • +2 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Studies Sup
Jun 19, 2013

Melanoma (Skin) Trial run by the NCI (MART-1 antigen, aldesleukin, gp100 antigen)

Completed
  • Melanoma (Skin)
  • MART-1 antigen
  • +3 more
  • Bethesda, Maryland
    Surgery Branch
Jun 18, 2013

Melanoma (Skin) Trial run by the NCI (MART-1 antigen, aldesleukin, gp100 antigen)

Completed
  • Melanoma (Skin)
  • MART-1 antigen
  • +3 more
  • Bethesda, Maryland
    Warren Grant Magnuson Clinical Center - NCI Clinical Studies Sup
Jun 17, 2013

Healthy Trial in Tel Aviv (Adjuvanted Multimeric-001 250 Mcg, Multimeric-001 250 Mcg, Phosphate Buffered saline)

Completed
Has Results
  • Healthy
  • Adjuvanted Multimeric-001 250 Mcg
  • +6 more
  • Tel Aviv, Israel
    Tasmc Crc
Feb 20, 2013

Recurrent Melanoma, Stage IV Melanoma Trial in Chicago (aldesleukin, gp100:209-217(210M) peptide vaccine, laboratory biomarker

Completed
  • Recurrent Melanoma
  • Stage IV Melanoma
  • aldesleukin
  • +2 more
  • Chicago, Illinois
    Cancer and Leukemia Group B
Jan 15, 2013

Neovascular Maculopathy, Age Related Macular Degeneration Trial in Suita (VEGFR1 and VEGFR2)

Completed
  • Neovascular Maculopathy
  • Age Related Macular Degeneration
  • VEGFR1 and VEGFR2
  • Suita, Osaka, Japan
    Ophthalmology, Osaka University Medical School
Oct 14, 2012

Leukemia, Myelodysplastic Syndrome Trial in Houston (PR-1 vaccine)

Terminated
Has Results
  • Leukemia
  • Myelodysplastic Syndrome
  • PR-1 vaccine
  • Houston, Texas
    U.T. M.D. Anderson Cancer Center
Jul 10, 2012

Esophageal Cancer Trial in Osakasayama (URLC10)

Completed
  • Esophageal Cancer
  • URLC10
  • Osakasayama, Osaka, Japan
    department of surgery, Kinki University
Apr 4, 2012

Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV Trial in Malaysia (Recombinant Human rEGF-P64K/Montanide Vaccine)

Terminated
  • Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV
  • Recombinant Human rEGF-P64K/Montanide Vaccine
  • Kubang Kerian, Kelantan, Malaysia
  • +9 more
Sep 29, 2011

Melanoma (Skin), Non-melanomatous Skin Cancer Trial run by the CC (LMB-2 immunotoxin, MART-1 antigen, gp100 antigen)

Completed
  • Melanoma (Skin)
  • Non-melanomatous Skin Cancer
  • LMB-2 immunotoxin
  • +3 more
  • Bethesda, Maryland
  • +1 more
Jun 12, 2012

Influenza Trial in Tel Aviv (Multimeric-001 250 mcg, Adjuvanted Multimeric-001 250mcg, Placebo)

Completed
  • Influenza
  • Multimeric-001 250 mcg
  • +6 more
  • Tel Aviv, Israel
    Tasmc Crc
Jul 30, 2012